Savant Capital LLC Has $1.07 Million Position in Novo Nordisk A/S (NYSE:NVO)

Savant Capital LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,329 shares of the company’s stock after selling 251 shares during the quarter. Savant Capital LLC’s holdings in Novo Nordisk A/S were worth $1,069,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Alpha Cubed Investments LLC grew its stake in shares of Novo Nordisk A/S by 512.2% during the fourth quarter. Alpha Cubed Investments LLC now owns 13,800 shares of the company’s stock valued at $1,428,000 after purchasing an additional 11,546 shares during the last quarter. Brighton Jones LLC boosted its position in Novo Nordisk A/S by 6.9% in the 4th quarter. Brighton Jones LLC now owns 7,811 shares of the company’s stock valued at $808,000 after buying an additional 501 shares during the last quarter. Mission Wealth Management LP increased its stake in shares of Novo Nordisk A/S by 7.3% in the 4th quarter. Mission Wealth Management LP now owns 22,153 shares of the company’s stock valued at $2,292,000 after buying an additional 1,509 shares during the period. Pekin Hardy Strauss Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $265,000. Finally, Stegent Equity Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $330,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $123.08 on Friday. The stock’s fifty day simple moving average is $127.21 and its 200 day simple moving average is $112.77. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $552.33 billion, a PE ratio of 42.44, a PEG ratio of 2.07 and a beta of 0.43. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. On average, research analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.